(redirected from Receptor tyrosine kinases)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia.
See: receiver
Mentioned in ?
References in periodicals archive ?
A team of researchers led by Jeffrey Engelman, at Massachusetts General Hospital Cancer Center, Boston, has now identified a potential way to effectively use receptor tyrosine kinases inhibitors to treat individuals with KRAS mutant colorectal cancers -- combine them with inhibitors of the MEK/ERK signaling pathway.
The largest subfamily of receptor tyrosine kinases is the Eph family, which has 14 fully sequenced members.
Kolltan's primary focus is to create novel biologic agents that can modulate the function of receptor tyrosine kinases (RTKs).
About Lenvatinib Lenvatinib, discovered and developed by Eisai, is an oral, multiple receptor tyrosine kinase inhibitor with a unique binding mode that selectively inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors (VEGFR1 [FLT1], VEGFR2 [KDR], and VEGFR3 [FLT4]), in addition to other proangiogenic and oncogenic pathway-related receptor tyrosine kinases (including fibroblast growth factor[FGF] receptors FGFR1, 2, 3, and 4; the platelet-derived growth factor[PDGF] receptor PDGFR[eth]; KIT; and RET) involved in tumor proliferation.
Soon after it was recognized as a growth factor-like molecule, as it interacted with receptor tyrosine kinases (RTKs) of the TAM family; Tyro3, Axl, and MerTK.
A special section is included in this year's edition on [Beta]-arrestins with topics that include the role of [Beta]-arrestin-mediated signaling in chemotaxis cellular process, their role in regulating signaling by receptor tyrosine kinases (RTKs), and the role of G protein- coupled receptor kinases and arrestins.
The spin-out transaction includes the transfer of all small molecule related assets, including a yeast-cell based, high-throughput screening platform for receptor tyrosine kinases (RTKs), and a number of specific and potent kinase inhibitors.
Craig Venter Institute (Rockville, MD), Ludwig Institute for Cancer Research, and The Johns Hopkins University School of Medicine identified three novel mutations in two receptor tyrosine kinases in glioblastoma tumors using high throughput sequencing.
Telatinib is an oral small molecule drug that inhibits the VEGFR, PDGFR and KIT receptor tyrosine kinases.
Proceeds Will Advance Proprietary Biologic Product Candidates Targeting Receptor Tyrosine Kinases
with overexpresssion of HER2/neu or overexpression of epidermal growth factor receptor, are treated with strongly binding PPAR gamma ligands, and patients affected with cancer associated with overexpression of at least one member of the class I family of receptor tyrosine kinases selected from the group consisting of HER-2/neu and epidermal growth factor rector, comprising administering to said patient a therapeutically effective amount of a ligand of peroxisome proliferator-activated receptor gamma (PPAR gamma) which has a pKi of at least 4.
Schlessinger for his work in elucidating the mechanism of action of receptor tyrosine kinases and their intracellular signaling pathways.

Full browser ?